REVIEW article
Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
Volume 12 - 2025 | doi: 10.3389/fmolb.2025.1583446
This article is part of the Research TopicEpigenetic Regulation in FibrosisView all articles
EPIGENETIC MODIFICATIONS IN CARDIAC FIBROSIS: RECENT EVIDENCE OF NEW PHARMACOLOGICAL TARGETS
Provisionally accepted
Samir José Bolívar González1,2*
Marian Perez Cantillo1,2
Evelyn Mendoza-Torres3
Jairo Castellar4
Mónica Gómez5- 1University of Atlántico, Barranquilla, Colombia
- 2Molecular Pharmacology Laboratory, Pharmacy and Pharmacology Research Group, Barranquilla, Colombia
- 3Faculty of Health, Exact and Natural Sciences, Universidad Libre de Colombia, Seccional Barranquilla., Barranquilla, Colombia
- 4Faculty of Health Sciences, Universidad de la Guajira, Riohacha, Colombia
- 5Universidad Libre de Colombia Seccional Barranquilla, Barranquilla, Atlántico, Colombia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cardiac fibrosis (CF) is characterized by the excessive deposition of collagen types I (COI I) and III (COI III), primarily mediated by cardiac fibroblasts (CFB). Recent advances in epigenetic research have enhanced our understanding of the molecular mechanisms underlying CF and have facilitated the identification of novel therapeutic strategies targeting key proteins and signaling pathways involved in its progression. Epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNAs (ncRNAs), are structural and chemical alterations that regulate gene expression and cellular responses without changing the DNA sequence. Investigating the role of epigenetic enzymes in CF may reveal promising pharmacological targets. This review summarizes current evidence on epigenetic modifications implicated in CF and discusses their potential as therapeutic targets for modulating this pathological process.
Keywords: cardiac fibrosis, cardiac fibroblasts, epigenetic modifications, cardiovascular epigenetics, non-coding RNA, DNA Methylation
Received: 25 Feb 2025; Accepted: 16 Apr 2025.
Copyright: © 2025 Bolívar González, Perez Cantillo, Mendoza-Torres, Castellar and Gómez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Samir José Bolívar González, University of Atlántico, Barranquilla, Colombia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.